BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16159455)

  • 21. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
    Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
    Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
    Dimai HP
    Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
    N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strontium ranelate in osteoporosis.
    Reginster JY
    Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
    Hiligsmann M; Bruyère O; Reginster JY
    Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial.
    Meunier PJ; Slosman DO; Delmas PD; Sebert JL; Brandi ML; Albanese C; Lorenc R; Pors-Nielsen S; De Vernejoul MC; Roces A; Reginster JY
    J Clin Endocrinol Metab; 2002 May; 87(5):2060-6. PubMed ID: 11994341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy.
    Blake GM; Fogelman I
    Clin Interv Aging; 2006; 1(4):367-75. PubMed ID: 18046914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
    Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
    Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Strontium Ranelate as a new therapeutic agent for osteoporosis].
    Imanishi Y; Nishizawa Y
    Clin Calcium; 2005 Jan; 15(1):25-8. PubMed ID: 15632469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strontium ranelate for osteoporosis?
    Drug Ther Bull; 2006 Apr; 44(4):29-32. PubMed ID: 16617933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strontium as therapy for osteoporosis.
    Marie PJ
    Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of strontium ranelate on spinal osteoarthritis progression.
    Bruyere O; Delferriere D; Roux C; Wark JD; Spector T; Devogelaer JP; Brixen K; Adami S; Fechtenbaum J; Kolta S; Reginster JY
    Ann Rheum Dis; 2008 Mar; 67(3):335-9. PubMed ID: 17965119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
    Roschger P; Manjubala I; Zoeger N; Meirer F; Simon R; Li C; Fratzl-Zelman N; Misof BM; Paschalis EP; Streli C; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Apr; 25(4):891-900. PubMed ID: 20437609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women.
    Rolland Y; Abellan Van Kan G; Gillette-Guyonnet S; Roux C; Boonen S; Vellas B
    Bone; 2011 Feb; 48(2):332-8. PubMed ID: 20817053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
    Reginster JY; Deroisy R; Jupsin I
    Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The efficacy of strontium ranelate (Osseor) on fractures in osteoporosis].
    Novak S
    Reumatizam; 2008; 55(2):75-7. PubMed ID: 19024282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.